EUVIMEDEUVIMED entdecken
Open Access

Targeting EZH2 oncogenic splicing: decoding the regulatory network and antisense correction

Md Rafikul Islam, Preeti Nagar, Naomi McNaughton, Shabiha Afroj Heeamoni, Md Mahbub Hasan, Shila Kandel, Israt Jahan Mukta, Panagiotis Tsakiroglou, William Brian Dalton, Omar Abdel-Wahab, Adrian R Krainer, Mohammad Alinoor Rahman

Genes & Development · 2026

DOI: 10.1101/gad.353628.126 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Genes & Development, 2026. Verfasst von Md Rafikul Islam und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry and Molecular Biology, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205, USA. Hauptthemen laut MEDLINE: Enhancer of Zeste Homolog 2 Protein, Oligonucleotides, Antisense, RNA Splicing, Gene Regulatory Networks. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIGMS NIH HHS, NCI NIH HHS, National Institute of General Medical Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Recurrent mutations in splicing factors (SFs) have been established as crucial drivers of tumorigenesis in several types of blood cancer and are also common in a variety of solid tumors. Mutations change the RNA-binding preferences of SFs, promote global splicing alterations, and often generate erroneous mRNAs that are then degraded by nonsense-mediated mRNA decay (NMD). Consequently, several critical genes linked to hematopoiesis are dysregulated, leading to blood cancer. Although the field has progressed considerably in identifying aberrant genes and affected pathways, effective therapies have not yet emerged. To address this key gap, we instigated a gene-specific targeted strategy by unlocking the regulatory network. As a proof of concept, we scrutinized a tumor suppressor gene, EZH2 , which is a bona fide target in SRSF2 mutated cancer. We precisely defined splicing cis -elements in EZH2 transcripts and illustrated the dynamic choreography of regulatory proteins in the entire splicing and NMD catalytic pathways. We then designed antisense oligonucleotides (ASOs) targeting important regulatory sites. Our lead ASO successfully corrects aberrant splicing and NMD, restores the expression and function of EZH2, and partially rescues hematopoietic defects and cellular properties. Our study demonstrates that ASO pharmacology is an actionable strategy for clinical development, challenging the existing paradigms in SF mutated cancers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Enhancer of Zeste Homolog 2 ProteinOligonucleotides, AntisenseRNA SplicingGene Regulatory NetworksAnimalsHumansNonsense Mediated mRNA DecaySerine-Arginine Splicing FactorsMiceMutationGene Expression Regulation, NeoplasticCell Line, Tumor

Stichwörter der Autor:innen

RNA splicingantisense oligonucleotide therapycancergene expressionnonsense-mediated mRNA decay

Substanzen

Enhancer of Zeste Homolog 2 ProteinOligonucleotides, AntisenseEZH2 protein, humanSerine-Arginine Splicing Factors

Autor:innen und Institutionen

  • Department of Biochemistry and Molecular Biology, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205, USA.
  • Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205, USA.
  • Division of Hematologic Malignancies and Bone Marrow Transplantation, Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland 21231, USA.
  • Molecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center (MSK), New York, New York 10065, USA.
  • Cold Spring Harbor Laboratory, Cold Spring Harbor, New York 11724, USA.
  • Department of Biochemistry and Molecular Biology, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205, USA; marahman@uams.edu.

Förderung

  • NIGMS NIH HHS
  • NCI NIH HHS
  • National Institute of General Medical Sciences
  • National Institutes of Health
  • Edward P. Evans Foundation
  • Winthrop P. Rockefeller Cancer Institute

Zitieren

APA

Islam, M. R., Nagar, P., McNaughton, N., Heeamoni, S. A., Hasan, M. M., Kandel, S., Mukta, I. J., Tsakiroglou, P., Dalton, W. B., Abdel-Wahab, O., Krainer, A. R., & Rahman, M. A. (2026). Targeting EZH2 oncogenic splicing: decoding the regulatory network and antisense correction. Genes & Development. https://doi.org/10.1101/gad.353628.126

Vancouver

Islam MR, Nagar P, McNaughton N, Heeamoni SA, Hasan MM, Kandel S, et al. Targeting EZH2 oncogenic splicing: decoding the regulatory network and antisense correction. Genes & Development. 2026. doi:10.1101/gad.353628.126

BibTeX
@article{Islam2026,
  author = {Islam, Md Rafikul and Nagar, Preeti and McNaughton, Naomi and Heeamoni, Shabiha Afroj and Hasan, Md Mahbub and Kandel, Shila and Mukta, Israt Jahan and Tsakiroglou, Panagiotis and Dalton, William Brian and Abdel-Wahab, Omar and Krainer, Adrian R and Rahman, Mohammad Alinoor},
  title = {Targeting EZH2 oncogenic splicing: decoding the regulatory network and antisense correction},
  journal = {Genes & Development},
  year = {2026},
  doi = {10.1101/gad.353628.126}
}
Kostenlos starten →